Tags

Type your tag names separated by a space and hit enter

Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
J Microbiol Biotechnol. 2020 Mar 28; 30(3):313-324.JM

Abstract

Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.

Authors+Show Affiliations

Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea. Bioenvironmental Science and Toxicology Division, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.Korea Zoonosis Research Institute and Genetic Engineering Research Institute, Jeonbuk National University, Jeollabuk-do 54896, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32238757

Citation

Ahn, Dae-Gyun, et al. "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)." Journal of Microbiology and Biotechnology, vol. 30, no. 3, 2020, pp. 313-324.
Ahn DG, Shin HJ, Kim MH, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-324.
Ahn, D. G., Shin, H. J., Kim, M. H., Lee, S., Kim, H. S., Myoung, J., Kim, B. T., & Kim, S. J. (2020). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). Journal of Microbiology and Biotechnology, 30(3), 313-324. https://doi.org/10.4014/jmb.2003.03011
Ahn DG, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. PubMed PMID: 32238757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). AU - Ahn,Dae-Gyun, AU - Shin,Hye-Jin, AU - Kim,Mi-Hwa, AU - Lee,Sunhee, AU - Kim,Hae-Soo, AU - Myoung,Jinjong, AU - Kim,Bum-Tae, AU - Kim,Seong-Jun, PY - 2020/4/3/entrez PY - 2020/4/3/pubmed PY - 2020/4/11/medline KW - 2019-nCoV KW - COVID-19 KW - SARS-CoV-2 KW - coronavirus KW - outbreak SP - 313 EP - 324 JF - Journal of microbiology and biotechnology JO - J Microbiol Biotechnol VL - 30 IS - 3 N2 - Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19. SN - 1738-8872 UR - https://www.unboundmedicine.com/medline/citation/32238757/Current_Status_of_Epidemiology_Diagnosis_Therapeutics_and_Vaccines_for_Novel_Coronavirus_Disease_2019__COVID_19__ L2 - http://www.jmb.or.kr/journal/view.html?doi=10.4014/jmb.2003.03011 DB - PRIME DP - Unbound Medicine ER -